Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
T-cell engagers are bispecific antibodies that bind CD3 on T cells and a surface antigen on target cells. Simultaneous binding forms an immune synapse that triggers T-cell activation and lysis of the target cell without the need for antigen presentation. Teclistamab and elranatamab pair CD3 with B-cell maturation antigen (BCMA), while talquetamab binds GPRC5D on myeloma cells. Glofitamab, mosunetuzumab and epcoritamab redirect T cells to CD20, and catumaxomab binds epithelial cell adhesion molecule (EpCAM). Further formats target CD19, CD33, CD123, prostate-specific membrane antigen (PSMA) and mucins, together with anti-CD3 antibodies.
Synonyms: NI-0401
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody that specifically targets CD3. This antibody plays a crucial role in modulating immune responses. It has demonstrated efficacy in NSG mice reconstituted with human hematopoietic stem cells, making it an invaluable tool for research into immune regulation and potential therapeutic applications.
Synonyms: XmAb-13676
Plamotamab (XmAb-13676) is a human bispecific antibody designed to target CD3 and CD20 simultaneously. This antibody facilitates the recruitment of cytotoxic T cells to CD20-expressing tumor cells, promoting targeted cell-mediated cytotoxicity. In vivo studies have demonstrated that Plamotamab effectively induces tumor regression. Additionally, it is associated with a mild hematologic reaction, highlighting its potential therapeutic benefits with manageable side effects. This product is pivotal for research focused on innovative cancer immunotherapies, particularly in the context of hematologic malignancies.
Synonyms: RG-6234; RO-7425781
Forimtamig (RG-6324) is a bispecific antibody designed for T-cell engagement, targeting GPRC5D and CD3. This molecule adopts a 2+1 configuration, incorporating two high-affinity binding sites for GPRC5D and a single site for CD3. It is engineered with a P329G LALA mutation in the Fc domain, which reduces binding to Fcγ receptors and C1q without affecting its interaction with the neonatal Fc receptor. The recommended isotype control for Forimtamig is Human IgG1 kappa. This antibody is pivotal in research focused on modulating immune responses, particularly in the context of cancer immunotherapy.
Obertamig is a humanized monoclonal antibody engineered to target CD3E and HLA-G. It features modifications in the CH2-CH3 regions and is composed of a hybrid structure that includes half of an immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv). This design enhances its specificity and efficacy in binding to its designated antigens, making it an ideal candidate for research in immune response modulation and therapeutic applications targeting these molecules.
Synonyms: JNJ-63898081
Voxalatamab (JNJ-63898081) is a bispecific IgG4 monoclonal antibody designed to target both PSMA (Prostate-Specific Membrane Antigen) and CD3. This antibody exhibits anticancer activity and is specifically developed for research in prostate cancer. Voxalatamab facilitates the engagement of T-cells to PSMA-expressing tumor cells, offering a strategic approach for investigating immune-mediated cancer cell eradication.
Synonyms: REGN5458
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody designed to selectively bind to the B cell maturation antigen (BCMA) on the surface of multiple myeloma (MM) cells and the CD3 receptor on T cells. This dual binding facilitates the targeted destruction of MM cells by directing and activating T cells to recognize and eliminate BCMA-expressing tumor cells. Linvoseltamab is primarily utilized in research focused on relapsed or refractory multiple myeloma (RRMM), providing a valuable tool for investigating novel therapeutic strategies in this challenging clinical area.
Synonyms: SPV-T3a
Dafsolimab (SPV-T3a) is a murine monoclonal antibody of the IgG2a subclass, targeting the CD3 antigen on T cells. This antibody functions by modulating and activating the CD3/T cell receptor complex, subsequently inducing T cell death. Dafsolimab is primarily utilized in research focused on understanding and treating graft-versus-host disease (GVHD), offering significant insights into T cell behaviors and immune responses in this condition.
The Anti-CD3 Antibody (OKT-3) is a chimeric mouse monoclonal antibody of the IgG2a, κ isotype, specifically designed to target human CD3. For optimal experimental control, it is recommended to use the Mouse IgG2a kappa Isotype Control. This antibody is pivotal for studies involving T-cell activation and response, making it an essential tool for immunological research.
Velinotamig is a bispecific antibody of the H-γ1_L-κ/H-γ1_L-κ type, designed to target CD3E and TNFRSF17. This antibody facilitates dual engagement, directing T-cell mediated immune responses specifically towards cells expressing TNFRSF17. It is utilized primarily in research focusing on the mechanisms of immune modulation and potential therapeutic strategies for diseases characterized by overexpression of TNFRSF17.
Ciduvectamig is a human IgG4 κ monoclonal antibody targeting CD3E and TMEFF2. For experimental rigor, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for specificity in binding to both CD3E, a key component in T-cell receptor signaling, and TMEFF2, which plays a role in cellular differentiation and proliferation. It is ideal for research applications investigating immune response modulation and cancer biology.
Cabotamig is a monoclonal antibody that targets both CD3E and CDH17. This dual-specificity allows for potential applications in modulating immune responses and investigating cellular adhesion processes in cancer research. Cabotamig is designed for use in various experimental settings, including flow cytometry, western blotting, and immunohistochemistry, to study the role of these proteins in immune cell function and tumor biology.
Synonyms: AMG-596
Etevritamab is a monoclonal antibody designed to target both CD3E and EGFR. This dual-specificity enables it to engage mechanisms related to T-cell activation and tumor cell inhibition, making it a valuable tool for research in immunotherapy and oncology. Etevritamab may be utilized in studies aiming to elucidate the pathways of immune response modulation and tumor growth suppression.
Xaluritamig is a monoclonal antibody designed to target both CD3E and STEAP1. This dual specificity allows for the potential engagement of immune system modulation through CD3E interaction and direct targeting of STEAP1, a protein implicated in several oncologic processes. Xaluritamig is primarily used in research focused on cancer immunotherapy and the study of immune response mechanisms.
Synonyms: GNC-038
Emfizatamab is a monoclonal antibody designed to target CD19, CD3E, TNFRSF9, and PD-L1. This multifunctional antibody facilitates the engagement of immune effector cells with cancer cells, potentially enhancing the immune response against malignant cells. It is primarily used in research focused on the mechanisms of immune modulation in oncology and the therapeutic potential in various cancers.
Pasritamig is a bispecific antibody designed to target KLK2 and CD3E. It is structured as a (H-γ1_L-κ)_scFvkh-G1(h-CH2-CH3) type, combining specificity to both antigens. This configuration enhances its application in directing immune system components to tumor cells expressing KLK2, thereby facilitating targeted immunotherapy. Pasritamig is primarily used in research focused on cancer therapy modalities, particularly in studies investigating prostate cancer and immune cell engagement mechanisms.
Synonyms: PF-06863135
Elranatamab (PF-06863135) is a human IgG2κ monoclonal antibody targeting CD3E and TNFRSF17. For optimal experimental control, it is recommended to use Human IgG2 kappa as an isotype control.
Podentamig is a chimeric antibody designed to target CD3E and TNFRSF17. It features a unique VH-VH'-(scFv-heavy -λ) configuration, enhancing its specificity and binding affinity for these antigens. This antibody is engineered for advanced research applications, focusing on the modulation of immune responses and the study of B-cell malignancies.
Synonyms: AMV-564; TandAb T564
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) designed to simultaneously target human CD33 and human CD3 antigens. This unique configuration facilitates the recruitment and activation of T cells against CD33-expressing cells, making it a valuable tool in the study of acute myeloid leukemia (AML). Vixtimotamab's dual targeting mechanism offers a promising approach for elucidating the interactions between immune cells and leukemia cells, providing significant insights into therapeutic strategies for AML.
Trevotamig is a bispecific antibody designed to target EPCAM and CD3E. This dimer-type antibody is engineered from the H-γ1_L-κ-scFvhl framework, offering precise dual specificity. It facilitates targeted immunotherapy by engaging both tumor cells and T-cells, making it a valuable tool for research in cancer immunology and therapeutic development.
Besufetamig is a bispecific monoclonal antibody designed to simultaneously target the programmed cell death protein 1 (PD-1) and the CD3ε chain. This innovative antibody modulates immune cell activity, demonstrating both immunosuppressive and antineoplastic properties. It is particularly valuable in cancer research, offering potential insights into novel immunotherapeutic strategies.
Avitotamig is a bispecific antibody designed to target both CD3E and CD33. This dual-targeting molecule is structured as a [H-γ1 _ L-κ-scFv heavy -κ]-dimer, optimizing its ability to engage immune cells and cancer cells simultaneously. This configuration enhances its therapeutic potential in targeting specific leukemic cells while activating cytotoxic T-cells, making it an invaluable tool for research in immunotherapy and oncology.
Odronextamab is a humanized IgG4 bispecific antibody engineered to target CD20 on B cells and CD3 on T cells. This dual specificity facilitates the direct engagement of T cells and malignant B cells, promoting potent anti-tumor responses. Primarily designed for oncology research, Odronextamab holds significant potential for elucidating the mechanisms of T cell-mediated cytotoxicity in B cell malignancies.
Surovatamig is a bispecific antibody engineered to target CD3D, CD3E, and CD19. This antibody features a (H-γ4_L-κ)_VH-G4(h-CH2-CH3) structure, designed to engage both T cells and B cells for enhanced therapeutic efficacy. Surovatamig is utilized primarily in research focused on the mechanisms of immune response and potential therapeutic applications in immunotherapy. This product is pivotal for studies involving cell signaling and activation in immune cells, making it a valuable tool for investigations into novel cancer treatments and autoimmune disease therapies.
Synonyms: ABBV-383; TNB 383B
Etentamig is a bispecific T-cell engager (BiTE) targeting both B-cell maturation antigen (BCMA) and the CD3 complex on T cells. This dual specificity enables Etentamig to simultaneously inhibit BCMA activity and activate the CD3 signaling pathway in T cells. It is primarily utilized in research focused on multiple myeloma and immunoglobulin light chain amyloidosis, with potential applications in exploring its effects on cardiovascular diseases. This makes Etentamig a valuable tool for advancing understanding of disease mechanisms and therapeutic strategies in these areas.
Synonyms: XmAb-18087
Tidutamab (XmAb-18087) is a humanized, affinity-optimized bispecific antibody designed to target both the somatostatin receptor 2 (SSTR2) and the CD3 epsilon subunit of the T-cell receptor. This antibody features a complete Fc domain, which enhances its stability and prolongs its serum half-life. Tidutamab facilitates the elimination of SSTR2-expressing tumor cells through the mechanism of redirected T-cell-mediated cytotoxicity (RTcC), offering a targeted approach in cancer immunotherapy.
